Marietta Investment Partners LLC Buys 13,741 Shares of Halozyme Therapeutics, Inc. $HALO

Marietta Investment Partners LLC boosted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 38.9% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 49,042 shares of the biopharmaceutical company’s stock after buying an additional 13,741 shares during the quarter. Marietta Investment Partners LLC’s holdings in Halozyme Therapeutics were worth $3,170,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. DLD Asset Management LP raised its position in shares of Halozyme Therapeutics by 20.0% during the third quarter. DLD Asset Management LP now owns 30,000,000 shares of the biopharmaceutical company’s stock worth $2,200,200,000 after acquiring an additional 5,000,000 shares during the last quarter. Norges Bank acquired a new stake in Halozyme Therapeutics in the fourth quarter worth about $128,201,000. William Blair Investment Management LLC acquired a new stake in Halozyme Therapeutics in the fourth quarter worth about $124,031,000. Voloridge Investment Management LLC bought a new stake in Halozyme Therapeutics during the 3rd quarter worth about $77,587,000. Finally, Qube Research & Technologies Ltd acquired a new position in Halozyme Therapeutics during the 2nd quarter valued at about $51,295,000. 97.79% of the stock is currently owned by institutional investors.

Insider Activity at Halozyme Therapeutics

In other news, Director Mahesh Krishnan sold 7,304 shares of the business’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the transaction, the director owned 14,462 shares of the company’s stock, valued at $1,084,650. The trade was a 33.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $76.71, for a total transaction of $124,653.75. Following the completion of the sale, the director owned 42,044 shares of the company’s stock, valued at approximately $3,225,195.24. This represents a 3.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 72,179 shares of company stock worth $5,052,400. 2.50% of the stock is currently owned by company insiders.

Halozyme Therapeutics Price Performance

Shares of HALO opened at $79.45 on Monday. The stock has a market cap of $9.42 billion, a P/E ratio of 28.58, a price-to-earnings-growth ratio of 0.33 and a beta of 0.84. Halozyme Therapeutics, Inc. has a 1 year low of $53.33 and a 1 year high of $82.22. The stock’s 50-day moving average price is $69.41 and its two-hundred day moving average price is $69.46. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. The company had revenue of $376.71 million during the quarter, compared to analysts’ expectations of $358.60 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.Halozyme Therapeutics’s revenue was up 42.2% on a year-over-year basis. During the same period in the prior year, the business posted $1.11 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, equities analysts predict that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on HALO shares. UBS Group reaffirmed a “buy” rating and issued a $90.00 target price on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, May 12th. Benchmark reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, June 16th. Eight research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Halozyme Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $81.60.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.